Phreesia, Inc. (PHR)

Phreesia's stock price has decreased over the past year. Key events include achieving its first net income positive quarter in Q2 Fiscal 2025, the acquisition of AccessOne in September 2025, and a 13% year-over-year increase in total revenue reported in Q3 Fiscal 2026. Management raised the Adjusted EBITDA outlook for fiscal year 2026 and introduced a revenue outlook for fiscal 2027. Strong investor optimism surrounded Phreesia's recent AI integrations. Phreesia's shares were pressured by a downgrade from Zacks Research, and there was insider selling of company stock in October 2025. Institutional ownership saw changes with some investors trimming stakes while others increased positions.

Phreesia experiences some demand seasonality, particularly in its payment processing business, with revenue typically highest during the first fiscal quarter due to the reset of health plan deductibles. The broader Healthcare sector also exhibits a seasonal strength period, generally running from April 25 to December 4. However, only five years of data are available for Phreesia, which may be insufficient for a fully reliable seasonal analysis specific to the company.

Phreesia, Inc. is a SaaS company in the Healthcare Technology sector, founded in 2005. It provides an integrated software and payment platform to streamline healthcare workflows and enhance patient engagement in the United States and Canada. Its solutions include appointment scheduling, registration automation, revenue cycle management, network solutions for patient communication, and AI integrations like Phreesia VoiceAI. The platform is deployed through mobile devices, tablets, web-based dashboards, and on-site kiosks, and also includes MediFind Provider Directory.

Phreesia, Inc. primarily operates in the United States and Canada, with a presence in all 50 U.S. states, servicing over 4,300 healthcare clients in fiscal year 2025. Its headquarters are located in Wilmington, Delaware, United States.

Phreesia has received positive recognition for its innovation and growth in the healthcare technology sector. It was named to the 2025 Deloitte Technology Fast 500 list and TIME's 2025 World's Top HealthTech Companies list. Sara DiNardo, Phreesia's Vice President of Client Solutions, was named to Becker's Hospital Review's 2025 list of Rising Stars. Phreesia has been named to the Capterra Shortlist multiple times and has received positive analyst outlooks and continued institutional interest.

Phreesia, Inc. is predominantly owned by institutional shareholders, who hold 99.80% of the company's shares, while insiders own 27.00% and retail investors hold 0.00%. Major institutional owners include Vanguard Group Inc and BlackRock, Inc.. The largest individual Phreesia shareholder, considered an insider, is Hlm Venture Partners II LP. Founders and executives collectively maintained an 8.53% stake as of June 2025.